Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers
References (16)
- et al.
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Eur J Pharmacol
(1970) - et al.
Minimal maintenance medication: Effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients
Compr Psychiatry
(1983) - et al.
The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations
Psychoneuroendocrinology
(1980) Schizophrenics fully remitted on neuroleptics for 3–5 years—To stop or continue drugs?
Br J Psychiatry
(1981)- et al.
Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization—A reevaluation
Arch Gen Psychiatry
(1967) - et al.
Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial
Br Med J
(1973) - et al.
Low-dose neuroleptic treatment of outpatient schizophrenics
Arch Gen Psychiatry
(1983)
Cited by (31)
Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials
2021, The Lancet PsychiatryCitation Excerpt :22 references were included in the meta-analysis, reporting on 24 individual trials and 3282 individuals. Altogether, 18 randomised controlled trials were double-blind (n=2838),21–44 while six were open-label or single-blind (n=444; table 1).31–42 Altogether, 1777 individuals were in the standard dose group, 726 in the low dose group, and 779 in the very low dose group.
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics
2017, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Combining low-potency antipsychotics with first or second generation antipsychotics is lacks the risk of dependence, withdrawal and recurrence of anxiety following cessation of the treatment (Sim et al., 2015). Moreover, possible pharmacodynamic interactions including amplified dopaminergic and noradrenergic blockade may prevent psychotic relapses (Nishikawa et al., 1985). Widely prescribed low-potency antipsychotics include chlorprothixene, levomepromazine, melperone, pipamperone and prothipendyl.
When is antipsychotic polypharmacy supported by research evidence? Implications for QI
2008, Joint Commission Journal on Quality and Patient SafetyCitation Excerpt :Three of the trials studied samples with mixed diagnoses,65–67 whereas three studied schizophrenia or schizoaffective disorder.68–70 Of the four trials reporting clinical outcomes, three reported no improvement,65,66,69 while the fourth study reported mixed results.70 Multiple antipsychotics were more beneficial than monotherapy at lower dosages but no better than monotherapy at higher dosages.70
Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications
1997, Progress in Neuro-Psychopharmacology and Biological PsychiatryTreatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
1993, Pharmacology and Therapeutics